People living with autoimmune diseases or other chronic inflammatory conditions often face unique and sometimes isolating challenges. Pfizer is fiercely committed to advancing scientific breakthroughs to address the unmet needs of these patients. Learn how Pfizer is progressing pipeline therapies for dermatologic conditions like alopecia areata and atopic dermatitis – all while empowering these patient communities through campaigns to foster awareness and acceptance. 

No matter the circumstances, advancing life-saving research for people living with cancer remains a priority for Pfizer. The U.S. FDA approved two Pfizer treatments: Braftovi®plus cetuximab for adults with metastatic colorectal cancer and Bavencio®plus chemotherapy for adults with advanced urothelial carcinoma. Beyond these approvals, Pfizer reinforced the importance of regular cancer screenings with the launch of the “Get It Done” campaign.​​​​​​​

Pfizer’s work in rare disease continued with several promising clinical-stage developments in gene therapy. Notably, Pfizer’s therapeutic candidate for Duchenne muscular dystrophy was granted fast-track designation by the U.S. FDA. For patients living with severe hemophilia A, a groundbreaking Phase 1/2 trial exploring a potential single-dose treatment option revealed positive findings.

In addition to leading the charge for the development of a COVID-19 vaccine, Pfizer continued to advance vaccine candidates for underserved patient populations worldwide while expanding crucial disease surveillance and vaccine efficacy data resources for the industry at large.

Antimicrobial resistance (AMR) is a serious global public health threat. In 2020, Pfizer joined the AMR Action Fund as part of its ongoing commitment to alleviate the global burden of AMR through funding and development of novel antibiotics. Pfizer is also partnering with local governments and health authorities in sub-Saharan Africa to improve AMR data collection across the region.